Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | LPL | P06858 | 12/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27185327 | 0.83 | CA1 (0.43) | CA1CA2CA9CA12CA3 | |
| SCHEMBL14858152 | 0.77 | PKM (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL14857832 | 0.75 | CA1 (0.47) | CA1CA2CA9CA12CA3 | |
| SCHEMBL21729587 | 0.75 | LPL (0.38) | CA1CA2CA9CA12CA3 | |
| SCHEMBL28726287 | 0.72 | ALDH1A1 (0.42) | CA1CA2CA9CA12CA3 | |
| SCHEMBL13324266 | 0.72 | HTT (0.36) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3187210 | 0.72 | FFAR1 (0.46) | CA1CA2CA9CA12CA3 | |
| SCHEMBL25176691 | 0.71 | LPL (0.46) | CA1CA2CA9CA12CA3 | |
| SCHEMBL28487 | 0.70 | LPL (0.44) | CA1CA2CA9CA12CA3 | |
| SCHEMBL21201773 | 0.68 | LPL (0.43) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258327-B2 | 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2025-03-25 | — | — | US | disclosed |
| US-20230085912-A1 | 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2023-03-23 | — | — | US | disclosed |
| WO-2023027516-A1 | 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | YUHAN CORPORATION (KR) | 2023-03-02 | — | — | WO | disclosed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | SMYD3, SMYD2, EHMT1 | CA1 3853/4885CA2 3099/4885CA9 1653/4885 |
| US-20230085912-A1 | 5-MEMBERED HETEROARYL-CONTAINING AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | CA1 4846/4885CA2 3680/4885CA9 3446/4885 |
| US-12258327-B2 | 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | CA1 4846/4885CA2 3680/4885CA9 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.